 PALO ALTO, Calif., Aug. 24, 2021 GLOBE NEWSWIRE -- 180 Life Sciences Corp. NASDAQ: ATNF 180 Life Sciences or the Company, a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the closing of its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock at a combined purchase price of 6.00 per share and accompanying warrant. The warrants are exercisable immediately at an exercise price of 7.50 per share and will expire five years from the date of issuance. Gross proceeds were approximately 15.0 million, before deducting placement agent fees and other offering expenses. The Company currently intends to use the net proceeds from this offering for general corporate purposes, working capital, and for the research and development of the Companys programs that are not funded by grants. 